Neuromuscular Strength Factors Influencing Vertical Jump Performance

April 24, 2026 updated by: Ramiz ARABACI, Uludag University

The Relationship Between Lower-Limb Muscle Strength and Related Parameters With Vertical Jump in Young Adult Males

This cross-sectional observational study is designed to comprehensively analyze the relationship between high-volume isokinetic muscle performance and explosive vertical jump capacity in healthy, recreationally active young adult males.

While traditional neuromuscular assessments frequently emphasize momentary peak force (Peak Torque), this study investigates the hypothesis that sustained mechanical work capacity (Total Work) and fatigue resistance (Fatigue Index) are more robust predictors of complex explosive tasks such as the countermovement jump (CMJ).

Methodology and Testing Protocol:

Participants will complete all assessments in a single laboratory session under controlled environmental conditions. The standardized testing sequence is as follows:

  1. Anthropometric and Body Composition Assessment: Participants' height, body mass, and body fat percentage will be measured using a multi-frequency bioelectrical impedance analyzer (InBody 270) following standard manufacturer protocols.
  2. Countermovement Jump (CMJ) Test: Following a standardized dynamic warm-up, participants will perform the CMJ test on a validated contact mat system (SmartJump). Participants will start from a standing position with hands placed on the hips to eliminate the influence of arm swing. They will perform a quick downward countermovement to approximately 90 degrees of knee flexion and execute a maximal vertical jump. Three trials will be conducted with a 30-second rest interval between attempts, and the highest jump will be recorded for analysis.
  3. Isokinetic Muscle Strength and Fatigue Test: After a 5-minute cycle ergometer warm-up, participants will undergo isokinetic testing on a computerized dynamometer (Humac Norm). Following familiarization trials, participants will execute a high-volume fatigue protocol consisting of 50 continuous, maximal concentric knee flexion and extension repetitions at an angular velocity of 180°/sec for both legs.

Primary Variables Analyzed:

From the isokinetic protocol, the primary variables of interest include Peak Torque (Nm), Average Power (W), Total Work (Nm), and the Isokinetic Fatigue Index (%). These mechanical metrics will be statistically analyzed against the maximum CMJ height (cm) to evaluate the predictive strength of sustained mechanical work capacity versus momentary force production on explosive motor performance.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

81

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population consists of healthy, recreationally active young adult males (mean age of approximately 24 years). Participants are moderately to highly physically active individuals (e.g., engaging in walking or jogging 1-2 times weekly) with no recent history of musculoskeletal pain, lower body surgery, or consumption of ergogenic aids.

Description

Inclusion Criteria:

  • Healthy young adult males
  • Moderately or highly physically active (e.g., walking or jogging 1-2 times weekly)
  • No consumption of any ergogenic aids or stimulants in the past 6 months

Exclusion Criteria:

  • Presence of any musculoskeletal pain
  • History of major lower body surgery within the last six months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Study cohort
Healthy, recreationally active young adult males who underwent body composition, countermovement jump (CMJ), and isokinetic muscle strength testing

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Isokinetic Extension Total Work (ETW)
Time Frame: Baseline (Single laboratory visit)
The total mechanical work capacity of the knee extensor muscles, measured in Newton-meters (Nm) over a 50-repetition maximal isokinetic protocol at 180°/sec.
Baseline (Single laboratory visit)
Countermovement Jump (CMJ) Height
Time Frame: Baseline (Single laboratory visit)
Maximum vertical jump height achieved during the CMJ test, measured in centimeters (cm) using a contact mat system.
Baseline (Single laboratory visit)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2024

Primary Completion (Actual)

November 1, 2025

Study Completion (Actual)

December 12, 2025

Study Registration Dates

First Submitted

April 24, 2026

First Submitted That Met QC Criteria

April 24, 2026

First Posted (Actual)

May 1, 2026

Study Record Updates

Last Update Posted (Actual)

May 1, 2026

Last Update Submitted That Met QC Criteria

April 24, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • E-87914409-050.03.04-230006086

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be publicly distributed to protect participant privacy and maintain confidentiality, in accordance with the ethics committee approval. However, de-identified raw data can be made available upon reasonable request to the principal investigator.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Conditions or Focus of Study

Subscribe